The present invention is directed to novel compounds and pharmaceutical
compositions that inhibit the binding of the SDF-1 chemokine to the
chemokine receptor CXCR4 and/or the binding of the SDF-1 or I-TAC
chemokines to the chemokine receptor CCXCKR2 (CXCR7). These compounds are
useful in preventing tumor cell proliferation, tumor formation,
metastasis, inflammatory diseases, treatment of HIV infectivity,
treatment of stem cell differentiation and mobilization disorders, and
ocular disorders.